1-(β-D-Lyxofuranosyl)-5-fluor-uracil | 13040-02-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(β-D-Lyxofuranosyl)-5-fluor-uracil
• 英文别名: 1-(β-D-Lyxofuranosyl>-5-fluor-uracil；1-β-Lyxofuranosyl-5-fluoruracil；5-fluoro-1-β-D-lyxofuranosyl-1H-pyrimidine-2,4-dione；1-beta-D-lyxofuranosyl-5-fluorouracil；1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidine-2,4-dione
• CAS: 13040-02-3
• 化学式: C₉H₁₁FN₂O₆
• 分子量: 262.195
• InChiKey: FHIDNBAQOFJWCA-FZGKIIIMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  119
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(β-D-Lyxofuranosyl)-5-fluor-uracil 在 铑 作用下， 以 水 为溶剂， 以to give 5-fluoro-4-hydroxy-1-β-D-lyxofuranosyl-tetrahydro-2(1H)-pyrimidinone and 5-fluoro-1-β-D-lyxofuranosyl-tetrahydro-2(1H)-pyrimidinone which的产率得到5-fluoro-4-hydroxy-1-beta-D-lyxofuranosyl-tetrahydro-2(1H)-pyrimidinone
  参考文献：
  名称：

  Organic compounds and process

  摘要：

  通过催化氢化，特别是在铑催化剂的存在下，产生了新型的氢化嘧啶核苷和核苷酸。这些新化合物被特别用于抑制脱氨酶，该酶会将胞嘧啶腺嘌呤糖苷转化为尿嘧啶腺嘌呤糖苷，从而使其失活。在哺乳动物和鸟类中，胞嘧啶腺嘌呤糖苷用于其抗病毒，特别是抗疱疹和抗细胞毒活性，以及用于消灭干扰抗生素生产的噬菌体。含有胞嘧啶腺嘌呤糖苷和氢化嘧啶核苷的新型制剂具有优势，可以提供持久的胞嘧啶腺嘌呤糖苷效果。

  公开号：

  US04017606A1

文献信息

• Drug formulations for cancer treatment
  申请人：The Regents of the University of California

  公开号：US11191774B2

  公开（公告）日：2021-12-07

  Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

  本文描述了含有这些化合物的化合物和药物制剂。还描述了制造和使用这些化合物的方法。这些化合物包括核碱基、核碱基类似物或其组合。在一个实施方案中，核碱基类似物与多柔比星结合并封装在脂质体中，用于抑制或防止癌细胞生长。进一步描述的是含有两种或两种以上治疗活性剂的药物组合物，这些活性剂封装在脂质体等囊泡内，其中活性剂的摩尔比可提供协同治疗效果。
• DRUG FORMULATIONS FOR CANCER TREATMENT
  申请人：The Regents of the University of California

  公开号：US20200306284A1

  公开（公告）日：2020-10-01

  Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
• US4017606A
  申请人：——

  公开号：US4017606A

  公开（公告）日：1977-04-12
• [EN] DRUG FORMULATIONS FOR CANCER TREATMENT<br/>[FR] FORMULATIONS DE MÉDICAMENTS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CALIFORNIA

  公开号：WO2017091767A2

  公开（公告）日：2017-06-01

  Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
• [EN] MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION<br/>[FR] MODULATEURS DE DUX4 POUR LA RÉGULATION DE LA FONCTION MUSCULAIRE
  申请人：GENEA IP HOLDINGS PTY LTD

  公开号：WO2017201585A1

  公开（公告）日：2017-11-30

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.